Back to List View Graph View

BCL2 apoptosis regulator

B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein and the founding member of the Bcl-2 family, a group of structurally related regulators of programmed cell death.

Where the papers sit

28 papers from the last 6 months study BCL2 apoptosis regulator directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 2 observational · 6 human data · 16 preclinical · 4 unclassified

Themes 4 themes

  • BCL2-Linked Mitochondrial Signaling

    Small molecules, natural extracts, peptides, RNAi constructs, and AI-guided repurposing are expanding ways to disrupt BCL2-linked survival in cancer. Mitochondrial apoptosis, ROS, mitophagy, cell-cycle arrest, and impaired migration recur across breast and colorectal models, with occasional extension to melanoma. Engineered dual RNAi and structure-guided peptides point toward more selective multi-pathway targeting than nonspecific cytotoxicity. Evidence is predominantly in vitro or computational, leaving delivery, selectivity, and clinical efficacy open.

    12 papers · 42.9%

  • BCL2-Targeted Blood Cancers

    Venetoclax is moving from established mantle cell lymphoma use toward combination and outcome-guided treatment in AML and aggressive B-cell lymphoma. PI3Kδ inhibition with YY-20394 plus ABT199 shows a combination strategy, while febrile neutropenia highlights treatment toxicity. Hi-C and molecular profiling recur as tools for detecting rearrangements and explaining relapse. Evidence remains largely retrospective or preclinical, with durable benefit and resistance still open.

    8 papers · 28.6%

  • Experimental Apoptosis Modulation

    Natural products, photodynamic therapy, and synthetic compounds are being screened for apoptosis-inducing activity across neurological, reproductive, and cancer models. BAX/BCL2 balance, caspase-3 activation, calcium or oxidative stress, and Annexin V/flow cytometry recur as readouts. Some interventions aim to protect normal tissue while killing resistant tumor cells. The work remains mechanistic and preclinical, without a common therapeutic lead.

    5 papers · 17.9%

  • Liver Disease Target Discovery

    Combination treatment is favored over sorafenib alone in liver cancer, with clomipramine proposed to overcome lysosomal sequestration and autophagy-linked resistance. Network pharmacology and docking broaden the search toward nutraceutical targets, while gut microbiota metabolites connect immune regulation to high-risk primary biliary cholangitis. Macrophages and autophagy recur as candidate mechanisms rather than validated clinical targets. The field is still generating hypotheses, and causal benefit in patients remains unresolved.

    3 papers · 10.7%

Papers

The 28 papers from the last 6 months that study BCL2 apoptosis regulator directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

BCL2-Linked Mitochondrial Signaling (12)
  1. Engineered dual RNAi prodrug for combined suppression of survival and cell cycle pathways in triple negative breast cancer treatment. Chemical communications (Cambridge, England) · 16 Oct 2026 PMID 42885730
  2. Rational structure-guided identification of a Bcl-2-targeting peptide with antiproliferative effects on colorectal cancer cells. Journal of enzyme inhibition and medicinal chemistry · 15 Oct 2026 PMID 42875898
  3. Tibetan medicine Anzhi Jinghua San alleviates chronic atrophic gastritis: attenuation of LysoPC-induced Bcl-2 suppression and inhibition of pyroptosis and apoptosis. Journal of ethnopharmacology · 13 Oct 2026 PMID 42869398
  4. Targeting BCL-2 through Deep Learning-Based Drug Repurposing: A Multimodal Approach Combining Diffusion-Based Generative Modeling, Neural Relational Inference, and In Vitro Validation. Journal of chemical information and modeling · 14 Sept 2026 PMID 42734502
  5. CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2. Medical oncology (Northwood, London, England) · 5 Sept 2026 PMID 42700291
  6. Berberine Modulates Mitophagy-Related Gene Expression and Suppresses Breast Cancer Cells: A Multi-Omics and Experimental Study. Cell biochemistry and biophysics · 26 Aug 2026 PMID 42645668
  7. A pilot single-case longitudinal multi-omics of canine oral melanoma characterizes endogenous mutation patterns and radiotherapy-associated responses. Gene · 24 Jun 2026 PMID 42342053
  8. Discovery of new thiazolyl hydrazone derivatives as anti-breast cancer agents: Synthesis, biological evaluation and in silico studies. Bioorganic chemistry · 19 Jun 2026 PMID 42320114
  9. Reverse engineering of BNIP3 identifies a mitochondrial protective peptide. Nature communications · 17 Jun 2026 PMID 42309990
  10. Bisphenol A exacerbates diabetic foot ulcers through disruption of immune microenvironment and repair processes: a multi-omics analysis of environmental exposure mechanisms. Drug and chemical toxicology · 15 Jun 2026 PMID 42298305
  11. Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
  12. Ethanolic extract of Otostegia fruticosa induces ROS-dependent apoptosis and reduces migration of MDA-MB-231 cells in vitro. PloS one · 26 May 2026 PMID 42189838
BCL2-Targeted Blood Cancers (8)
  1. Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. Molecular biology reports · 7 Sept 2026 PMID 42704540
  2. Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis. European journal of clinical pharmacology · 1 Aug 2026 PMID 42541584
  3. Mechanistic study on the treatment of androgenetic alopecia with Platycladus orientalis leaf extract via regulation of the VEGFA/Bcl2 pathway: An in silico and in vitro study. Medicine · 18 Jul 2026 PMID 42469978
  4. Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma. Blood advances · 10 Jul 2026 PMID 42431614
  5. PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells. Oncology reports · 19 Jun 2026 PMID 42318952
  6. Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. Blood advances · 17 Jun 2026 PMID 42308239
  7. Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
  8. First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma. Cancer discovery · 21 May 2026 PMID 42166034
Experimental Apoptosis Modulation (5)
  1. Anticancer activity of asiatic acid in cisplatin-resistant human neuroblastoma SH-SY5Y and its unaffected effect on human neural stem cells. PloS one · 15 Sept 2026 PMID 42743141
  2. Effects of interstitial photodynamic therapy on transplanted tumors of human lung adenocarcinoma A549 cells in nude mice. Lasers in medical science · 10 Jul 2026 PMID 42429993
  3. Resveratrol Ameliorates PTZ-Induced Seizure Activity and Diaphragm Muscle Dysfunction by Regulating Calcium Handling and Apoptotic Pathways in Rats. Molecular neurobiology · 9 Jul 2026 PMID 42426356
  4. Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats. Journal of molecular histology · 18 Jun 2026 PMID 42315798
  5. Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
Liver Disease Target Discovery (3)
  1. Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
  2. A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. PloS one · 1 Jul 2026 PMID 42384725
  3. Clomipramine potentiates sorafenib efficacy in experimental hepatocellular carcinoma by targeting lysosomal sequestration and modulating the cathepsin B/Bcl-2/Beclin-1 axis. Molecular biology reports · 30 Jun 2026 PMID 42377685

By study type

Observational studies and case reports (2)
  1. Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis. European journal of clinical pharmacology · 1 Aug 2026 PMID 42541584
  2. Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
Human data, design not indexed (6)
  1. Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. Molecular biology reports · 7 Sept 2026 PMID 42704540
  2. CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2. Medical oncology (Northwood, London, England) · 5 Sept 2026 PMID 42700291
  3. Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
  4. Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma. Blood advances · 10 Jul 2026 PMID 42431614
  5. Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. Blood advances · 17 Jun 2026 PMID 42308239
  6. First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma. Cancer discovery · 21 May 2026 PMID 42166034
Preclinical: animal, cell and lab studies (16)
  1. Engineered dual RNAi prodrug for combined suppression of survival and cell cycle pathways in triple negative breast cancer treatment. Chemical communications (Cambridge, England) · 16 Oct 2026 PMID 42885730
  2. Rational structure-guided identification of a Bcl-2-targeting peptide with antiproliferative effects on colorectal cancer cells. Journal of enzyme inhibition and medicinal chemistry · 15 Oct 2026 PMID 42875898
  3. Anticancer activity of asiatic acid in cisplatin-resistant human neuroblastoma SH-SY5Y and its unaffected effect on human neural stem cells. PloS one · 15 Sept 2026 PMID 42743141
  4. Targeting BCL-2 through Deep Learning-Based Drug Repurposing: A Multimodal Approach Combining Diffusion-Based Generative Modeling, Neural Relational Inference, and In Vitro Validation. Journal of chemical information and modeling · 14 Sept 2026 PMID 42734502
  5. Mechanistic study on the treatment of androgenetic alopecia with Platycladus orientalis leaf extract via regulation of the VEGFA/Bcl2 pathway: An in silico and in vitro study. Medicine · 18 Jul 2026 PMID 42469978
  6. Effects of interstitial photodynamic therapy on transplanted tumors of human lung adenocarcinoma A549 cells in nude mice. Lasers in medical science · 10 Jul 2026 PMID 42429993
  7. Resveratrol Ameliorates PTZ-Induced Seizure Activity and Diaphragm Muscle Dysfunction by Regulating Calcium Handling and Apoptotic Pathways in Rats. Molecular neurobiology · 9 Jul 2026 PMID 42426356
  8. A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. PloS one · 1 Jul 2026 PMID 42384725
  9. Clomipramine potentiates sorafenib efficacy in experimental hepatocellular carcinoma by targeting lysosomal sequestration and modulating the cathepsin B/Bcl-2/Beclin-1 axis. Molecular biology reports · 30 Jun 2026 PMID 42377685
  10. Discovery of new thiazolyl hydrazone derivatives as anti-breast cancer agents: Synthesis, biological evaluation and in silico studies. Bioorganic chemistry · 19 Jun 2026 PMID 42320114
  11. PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells. Oncology reports · 19 Jun 2026 PMID 42318952
  12. Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats. Journal of molecular histology · 18 Jun 2026 PMID 42315798
  13. Reverse engineering of BNIP3 identifies a mitochondrial protective peptide. Nature communications · 17 Jun 2026 PMID 42309990
  14. Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
  15. Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
  16. Ethanolic extract of Otostegia fruticosa induces ROS-dependent apoptosis and reduces migration of MDA-MB-231 cells in vitro. PloS one · 26 May 2026 PMID 42189838
Unclassified: not yet indexed with MeSH (4)
  1. Tibetan medicine Anzhi Jinghua San alleviates chronic atrophic gastritis: attenuation of LysoPC-induced Bcl-2 suppression and inhibition of pyroptosis and apoptosis. Journal of ethnopharmacology · 13 Oct 2026 PMID 42869398
  2. Berberine Modulates Mitophagy-Related Gene Expression and Suppresses Breast Cancer Cells: A Multi-Omics and Experimental Study. Cell biochemistry and biophysics · 26 Aug 2026 PMID 42645668
  3. A pilot single-case longitudinal multi-omics of canine oral melanoma characterizes endogenous mutation patterns and radiotherapy-associated responses. Gene · 24 Jun 2026 PMID 42342053
  4. Bisphenol A exacerbates diabetic foot ulcers through disruption of immune microenvironment and repair processes: a multi-omics analysis of environmental exposure mechanisms. Drug and chemical toxicology · 15 Jun 2026 PMID 42298305